Sedation using dexmedetomidine in pediatric burn patients

Journal of Burn Care and Research

Volumn 27, Issue 2, 2006, Pages 206-210

  Walker, James ^a   MacCallum, Matt ^a   Fischer, Carl ^a,b   Kopcha, Robert ^b   Saylors, Roy ^b   McCall, John ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; DEXMEDETOMIDINE; OPIATE; HYPNOTIC SEDATIVE AGENT; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; ARTIFICIAL VENTILATION; BURN; BURN PATIENT; CHILD; DOSE CALCULATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFANT; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SEDATION; TRANQUILIZING ACTIVITY; ADOLESCENT; BLOOD; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PAIN; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANALGESICS, OPIOID; BLOOD GLUCOSE; BURNS; CHILD; CHILD, PRESCHOOL; DEXMEDETOMIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFANT; INFUSIONS, INTRAVENOUS; MALE; MIDAZOLAM; MORPHINE; PAIN; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES;

EID: 33745336884     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/01.BCR.0000200910.76019.CF     Document Type: Article

References (17)

1. Ostermann ME, Keenan SP, Seiferling RA, et al. Sedation in the intensive care unit: a systematic review. JAMA 2000;283:1451-59.
2. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-36.
3. Sheridan R, Stoddard F, Querzoli E. Management of background pain and anxiety in critically burned children requiring protracted mechanical ventilation. J Burn Care Rehabil 2001;22:150-3.
4. Virtanen R, Savola JM, Saaano V, et al. Characterization of selectivity, specificity and potency of dexmedetomidine as alpha-2-adrenoceptor agonist. Eur J Pharmacol 1988;150:9-14.
5. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992;77:1125-33.
6. Hall JE, Uhrich T, Barney JA, et al. Sedative, amnestic, and analgesic properties of small dose dexmedetomidine infusions. Anesth Analg 2000;90:699-705.
7. Tobias JK, Berkenbosch JW. Initial experience with dexmedetomidine in paediatric aged patients. Paediatr Anaesth 2002;12:171-5.
8. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-67.
9. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perspectives. Br J Anaesth 2001;87:684-90.
10. Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003;17:576-84.
11. Sheridan RL, Keaney T, Stoddard F, et al. Short-term propofol infusion as an adjunct to extubation in burned children. J Burn Care Rehabil 2003;24:356-60.
12. 2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003;98:428-36.
13. Tobias J, Berkenbosch J, Russo P. Additional experience with dexmedetomidine in pediatric patients. South Med J 2003;96:871-5.
14. Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J 2004;97:451-5.
15. Serlin S. Dexmedetomidine in Pediatrics: controlled studies needed. Anesth Analg 2004;98:1814.
16. Precedex labeling draft. Available at: www.fda.gov/cder/foi/label/1999/ 21038lbl.pdf. Accessed January 2, 2006.
17. Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic alpha-adrenergic pathways. Diabetes 1978;27:554-62.